ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
94,521.56
-0.62%
S&P 500
5,974.07
0.73%
Dow Jones
42,906.95
0.16%
US Dollar vs Yen
157.1675
0.40%
Brent Oil
72.74
0.03%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ

  6. Abivax SA (ABVX) 銘柄情報

Abivax SA

Abivax SA (ABVX)

Abivax
7.35
-0.30
(-3.92%)
終値： 12月24日 6:00AM
15分遅延
7.35
0.00
( 0.00% )
取引時間後: 7:00AM
15分遅延

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

主要統計と詳細

通貨
7.35
買値
7.00
売値
11.07
出来高
449,216
7.00 日の範囲 7.67
0.00 52 週間の範囲 0.00
時価総額
462.443M
前日終値
7.65
始値
7.60
時刻
41100
@
7.35
(priorref)
最終取引時間
06:08:33
財務取引量
US$ 3,259,148
VWAP
7.2552
平均取引量 (3 か月)
-
発行済株式数
62,917,479
配当利回り
-
PER
-3.02
1 株当たり利益 (EPS)
-2.35
歳入
4.62M
純利益
-147.74M

Abivax SA について

Abivax is focused on developing innovative treatments that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Abivax is focused on developing innovative treatments that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Preparations
ウェブサイト
www.abivax.com
本社
Paris, Paris, Fra
設立
-
Abivax SA is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker ABVX. The last closing price for Abivax was US$7.65. Over the last year, Abivax shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Abivax currently has 62,917,479 shares in issue. The market capitalisation of Abivax is US$481.32 million. Abivax has a price to earnings ratio (PE ratio) of -3.02.

ABVX 最新ニュース

その他のニュース

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

32分前
Edgar (US Regulatory)

Abivax Announces a Change to the Composition of its Board of Directors

Abivax Announces a Change to the Composition of its Board of Directors PARIS, France, December 23, 2024, 10:05 PM CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the...

2時間前
GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness

2024年11月27日
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

2024年11月20日
Edgar (US Regulatory)

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq PARIS, France, November 19, 2024 – 10:30PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq - ABVX) (“Abivax” or the...

2024年11月20日
GlobeNewswire Inc.

Form F-3 - Registration statement by foreign private issuers

2024年11月20日
Edgar (US Regulatory)

Abivax presents third quarter 2024 key financial information

Abivax presents third quarter 2024 key financial information PARIS, France, November 14, 2024, 10:00 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the...

2024年11月15日
GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

2024年11月15日
Edgar (US Regulatory)

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and...

2024年11月14日
GlobeNewswire Inc.

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation PARIS, France, October 7, 2024, 10:00...

2024年10月8日
GlobeNewswire Inc.
期間 †前日比前日比 %始値高値安値平均出来高VWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

ABVX - Frequently Asked Questions (FAQ)

What is the current Abivax share price?
The current share price of Abivax is US$ 7.35
How many Abivax shares are in issue?
Abivax has 62,917,479 shares in issue
What is the market cap of Abivax?
The market capitalisation of Abivax is USD 481.32M
What is the 1 year trading range for Abivax share price?
Abivax has traded in the range of US$ 0.00 to US$ 0.00 during the past year
What is the PE ratio of Abivax?
The price to earnings ratio of Abivax is -3.02
What is the cash to sales ratio of Abivax?
The cash to sales ratio of Abivax is 96.46
What is the reporting currency for Abivax?
Abivax reports financial results in EUR
What is the latest annual turnover for Abivax?
The latest annual turnover of Abivax is EUR 4.62M
What is the latest annual profit for Abivax?
The latest annual profit of Abivax is EUR -147.74M
What is the registered address of Abivax?
The registered address for Abivax is 7-11 BOULEVARD HAUSSMANN, PARIS, PARIS, 75009
What is the Abivax website address?
The website address for Abivax is www.abivax.com
Which industry sector does Abivax operate in?
Abivax operates in the PHARMACEUTICAL PREPARATIONS sector

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
MYNAMynaric AG
US$ 0.73
(66.05%)
6.45M
NCRANocera Inc
US$ 1.43
(60.58%)
3.51M
TIVCTivic Health Systems Inc
US$ 0.32
(42.60%)
5.8M
BNOXBionomics Ltd
US$ 0.353
(39.47%)
5.82M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.45
(11.63%)
12.66M
FRESFresh2 Group Ltd
US$ 0.55
(-35.29%)
17.88k
SLGLSol Gel Technologies Ltd
US$ 1.16
(-29.70%)
2.98M
ANEBAnebulo Pharmaceuticals Inc
US$ 1.0201
(-18.39%)
2.65k
APCXAppTech Payments Corporation
US$ 0.6872
(-17.81%)
176.2k
JZXNJiuzi Holdings Inc
US$ 1.45
(-12.12%)
312
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.45
(11.63%)
12.66M
DRCTDirect Digital Holdings Inc
US$ 5.6517
(2.76%)
7.43M
MYNAMynaric AG
US$ 0.73
(66.05%)
6.45M
BNOXBionomics Ltd
US$ 0.353
(39.47%)
5.82M
TIVCTivic Health Systems Inc
US$ 0.32
(42.60%)
5.8M

ABVX Discussion

投稿を表示

最近閲覧した銘柄

NASDAQ
ABVX
Abivax
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有